What is Lifesci Capital’s Forecast for TARS Q1 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Lifesci Capital issued their Q1 2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a report issued on Monday, March 16th. Lifesci Capital analyst F. Brisebois anticipates that the company will earn ($0.52) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.01) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The business had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million.

TARS has been the topic of a number of other research reports. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Mizuho started coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, November 20th. They set an “outperform” rating and a $100.00 price objective for the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Guggenheim lifted their price target on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $91.83.

Tarsus Pharmaceuticals Trading Down 2.2%

Shares of TARS opened at $68.24 on Thursday. Tarsus Pharmaceuticals has a 1-year low of $38.51 and a 1-year high of $85.25. The company has a market capitalization of $2.90 billion, a P/E ratio of -42.12 and a beta of 0.55. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. The firm’s 50 day simple moving average is $69.59 and its 200 day simple moving average is $70.20.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Deep Track Capital LP grew its holdings in Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after acquiring an additional 1,250,000 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Tarsus Pharmaceuticals by 34.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock worth $158,062,000 after purchasing an additional 491,326 shares during the period. Norges Bank purchased a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth about $19,095,000. M&T Bank Corp grew its stake in shares of Tarsus Pharmaceuticals by 11,730.0% in the fourth quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after purchasing an additional 433,424 shares during the last quarter. Finally, MPM Bioimpact LLC purchased a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $13,834,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Tarsus Pharmaceuticals

In other news, Director William J. Phd Link sold 12,500 shares of Tarsus Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $68.79, for a total value of $859,875.00. Following the transaction, the director owned 116,332 shares in the company, valued at approximately $8,002,478.28. The trade was a 9.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the transaction, the chief executive officer owned 857,991 shares in the company, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 8.97% of the stock is currently owned by company insiders.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to a “Strong‑Buy” and published a set of 2026 quarterly and full‑year EPS forecasts that are materially less negative than street consensus — they expect FY2026 EPS of ($1.01) vs. a consensus around ($3.17), and they project a positive Q4 2026 EPS of $0.09. The upgrade and less‑pessimistic FY outlook are supportive for the stock. Lifesci Upgrade / Estimates
• Neutral Sentiment: Analyst consensus still sits at a “Moderate Buy” on TARS, reflecting mixed views across the street — some analysts see upside if clinical/commercial execution improves, while consensus EPS remains negative for the year. Analyst Consensus
• Negative Sentiment: Insider selling: Director William J. Link disclosed a sale of 12,500 shares at an average price of $68.79 on March 16 — a large personal divestiture that may be viewed negatively by some investors as a signal to take profits or reduce exposure. SEC filing: Form 4

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.